Decoy Therapeutics (DCOY) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $1.17, -4.88% vs the prior close of $1.23.
- Volume 36.54K shares, 0.0x its 50-day average (light).
- New SEC filings: 424B3 (Oct 16, 2026).
- No new insider buys or sales reported since the prior session.
DCOY slides 4.9% to $1.17. Closed at $1.17, -4.88% vs the prior close of $1.23. Day range $1.16–$1.22, opened at $1.22.
DCOY daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — DCOY slides 4.9% to $1.17
- Closed at $1.17, -4.88% vs the prior close of $1.23. Day range $1.16–$1.22, opened at $1.22.
- Volume was 36.54K shares, 0.0x its 50-day average of 2.75M — lighter than usual.
- Price is -56.2% vs its 50-day average ($2.67) and -80.3% vs its 200-day average ($5.93).
- 52-week range $1.15–$54.00; today's close sits at 0% of that range, 97.8% below the 52-week high.
Oct 15, 2026 — DCOY jumps 5.1% to $1.23
- Closed at $1.23, +5.13% vs the prior close of $1.17. Day range $1.16–$1.28, opened at $1.16.
- Volume was 90.10K shares, 0.0x its 50-day average of 2.75M — lighter than usual.
- Price is -54.9% vs its 50-day average ($2.73) and -79.4% vs its 200-day average ($5.96).
- 52-week range $1.15–$55.92; today's close sits at 0% of that range, 97.8% below the 52-week high.
Oct 14, 2026 — DCOY slides 5.6% to $1.17, a 52-week low, 5 down days in a row
- Closed at $1.17, -5.65% vs the prior close of $1.24. Day range $1.15–$1.27, opened at $1.27.
- Volume was 89.10K shares, 0.0x its 50-day average of 2.75M — lighter than usual.
- Price is -58.0% vs its 50-day average ($2.79) and -80.5% vs its 200-day average ($6.00).
- 52-week range $1.15–$55.92; today's close sits at 0% of that range, 97.9% below the 52-week high.
- That makes 5 straight losses.
Oct 13, 2026 — DCOY slides 13.3% to $1.24, a 52-week low, 4 down days in a row
- Closed at $1.24, -13.29% vs the prior close of $1.43. Day range $1.21–$1.40, opened at $1.40.
- Volume was 166.70K shares, 0.1x its 50-day average of 2.75M — lighter than usual.
- Price is -56.5% vs its 50-day average ($2.85) and -79.4% vs its 200-day average ($6.03).
- 52-week range $1.21–$55.92; today's close sits at 0% of that range, 97.8% below the 52-week high.
- That makes 4 straight losses.
Oct 12, 2026 — DCOY dips 2.7% to $1.43, a 52-week low, 3 down days in a row
- Closed at $1.43, -2.72% vs the prior close of $1.47. Day range $1.41–$1.49, opened at $1.47.
- Volume was 56.40K shares, 0.0x its 50-day average of 2.75M — lighter than usual.
- Price is -50.9% vs its 50-day average ($2.91) and -76.4% vs its 200-day average ($6.06).
- 52-week range $1.41–$55.92; today's close sits at 0% of that range, 97.4% below the 52-week high.
- That makes 3 straight losses.
Oct 9, 2026 — DCOY slides 3.3% to $1.47, a 52-week low
- Closed at $1.47, -3.29% vs the prior close of $1.52. Day range $1.46–$1.52, opened at $1.49.
- Volume was 43.70K shares, 0.0x its 50-day average of 2.75M — lighter than usual.
- Price is -50.5% vs its 50-day average ($2.97) and -75.9% vs its 200-day average ($6.09).
- 52-week range $1.46–$55.92; today's close sits at 0% of that range, 97.4% below the 52-week high.
Oct 8, 2026 — DCOY slides 5.6% to $1.52, a 52-week low
- Closed at $1.52, -5.59% vs the prior close of $1.61. Day range $1.48–$1.62, opened at $1.58.
- Volume was 122.00K shares, 0.0x its 50-day average of 2.75M — lighter than usual.
- Price is -49.6% vs its 50-day average ($3.02) and -75.2% vs its 200-day average ($6.13).
- 52-week range $1.48–$55.92; today's close sits at 0% of that range, 97.3% below the 52-week high.
Oct 7, 2026 — DCOY jumps 3.9% to $1.61
- Closed at $1.61, +3.87% vs the prior close of $1.55. Day range $1.51–$1.64, opened at $1.55.
- Volume was 83.50K shares, 0.0x its 50-day average of 2.75M — lighter than usual.
- Price is -47.5% vs its 50-day average ($3.07) and -73.9% vs its 200-day average ($6.16).
- 52-week range $1.51–$55.92; today's close sits at 0% of that range, 97.1% below the 52-week high.
- SEC filings that day: S-1.
Oct 6, 2026 — DCOY slides 7.2% to $1.55, a 52-week low, 9 down days in a row
- Closed at $1.55, -7.19% vs the prior close of $1.67. Day range $1.55–$1.66, opened at $1.65.
- Volume was 127.90K shares, 0.0x its 50-day average of 2.77M — lighter than usual.
- Price is -50.3% vs its 50-day average ($3.12) and -75.0% vs its 200-day average ($6.19).
- 52-week range $1.55–$55.92; today's close sits at 0% of that range, 97.2% below the 52-week high.
- That makes 9 straight losses.
Oct 5, 2026 — DCOY slides 5.6% to $1.67, a 52-week low, 8 down days in a row
- Closed at $1.67, -5.65% vs the prior close of $1.77. Day range $1.65–$1.77, opened at $1.77.
- Volume was 105.70K shares, 0.0x its 50-day average of 2.76M — lighter than usual.
- Price is -47.1% vs its 50-day average ($3.16) and -73.2% vs its 200-day average ($6.22).
- 52-week range $1.61–$55.92; today's close sits at 0% of that range, 97.0% below the 52-week high.
- That makes 8 straight losses.
Oct 2, 2026 — DCOY slides 4.6% to $1.77, a 52-week low, 7 down days in a row
- Closed at $1.77, -4.58% vs the prior close of $1.86. Day range $1.61–$1.88, opened at $1.88.
- Volume was 252.00K shares, 0.1x its 50-day average of 2.76M — lighter than usual.
- Price is -45.1% vs its 50-day average ($3.23) and -71.7% vs its 200-day average ($6.26).
- 52-week range $1.61–$55.92; today's close sits at 0% of that range, 96.8% below the 52-week high.
- That makes 7 straight losses.
DCOY latest news & SEC filings
Every SEC filing by or about DCOY in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 16, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Oct 7, 2026 · Form S-1 — Registration statement (S-1)
Registration statement (S-1) — registering new shares, usually for an IPO or offering
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 23, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 3.02 — Sold unregistered shares.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 15, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Sep 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $227.63K (prior year $0)
- Net income: -$2.37M (prior year -$957.83K) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$4.46 (prior year -$81.21) (loss narrowed vs Jun 30, 2025)
Aug 4, 2026 · Form DEF 14A — Proxy statement
Proxy statement — agenda for the shareholder meeting (board elections, executive pay, votes)
Aug 4, 2026 · Form DEFA14A — Additional proxy materials
Additional proxy materials
Jul 24, 2026 · Form PRE 14A — Preliminary proxy statement
Preliminary proxy statement
Things to know before you trade DCOY
- Last results release: Jul 31, 2025 (8-K Item 2.02). Previous ones: Jan 17, 2025, Aug 10, 2023, Nov 10, 2022. Based on that rhythm, the next report is likely around Oct 30, 2025 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 9.06% (largest 25.2%). That is a volatile stock.
- Liquidity: about 6.84M shares (≈$8.00M) trade per day on average.
- 52-week position: $1.17 vs a range of $1.15–$54.00 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:12 on Mar 9, 2026, 1:15 on Aug 18, 2025
- Insider trades (Form 4, last 12 months, recent 25 shown): 8 open-market buys, 8 sales; latest: Arnold C Hanish sold 15 shares on Dec 30, 2025.
- Latest filings: 8-K Sep 23, 2026; 8-K Sep 15, 2026; 10-Q Aug 12, 2026.
- Share count: 655.18K shares outstanding (Aug 12, 2026), -91.4% vs a year earlier — the company has been reducing its share count.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
DCOY market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 1.22 | 1.22 | 1.16 | 1.17 | 36.54K |
| Oct 15, 2026 | 1.16 | 1.28 | 1.16 | 1.23 | 90.10K |
| Oct 14, 2026 | 1.27 | 1.27 | 1.15 | 1.17 | 89.10K |
| Oct 13, 2026 | 1.40 | 1.40 | 1.21 | 1.24 | 166.70K |
| Oct 12, 2026 | 1.47 | 1.49 | 1.41 | 1.43 | 56.40K |
| Oct 9, 2026 | 1.49 | 1.52 | 1.46 | 1.47 | 43.70K |
| Oct 8, 2026 | 1.58 | 1.62 | 1.48 | 1.52 | 122.00K |
| Oct 7, 2026 | 1.55 | 1.64 | 1.51 | 1.61 | 83.50K |
| Oct 6, 2026 | 1.65 | 1.66 | 1.55 | 1.55 | 127.90K |
| Oct 5, 2026 | 1.77 | 1.77 | 1.65 | 1.67 | 105.70K |
| Oct 2, 2026 | 1.88 | 1.88 | 1.61 | 1.77 | 252.00K |
| Oct 1, 2026 | 1.96 | 1.99 | 1.79 | 1.86 | 167.60K |
| Sep 30, 2026 | 2.16 | 2.20 | 1.91 | 1.97 | 238.00K |
| Sep 29, 2026 | 2.31 | 2.38 | 2.01 | 2.13 | 709.10K |
| Sep 28, 2026 | 2.98 | 2.99 | 2.23 | 2.31 | 549.70K |
| Sep 25, 2026 | 3.11 | 3.41 | 3.05 | 3.09 | 441.80K |
| Sep 24, 2026 | 3.71 | 3.71 | 3.10 | 3.11 | 1.39M |
| Sep 23, 2026 | 4.40 | 4.71 | 3.75 | 3.85 | 26.77M |
| Sep 22, 2026 | 5.15 | 7.61 | 3.00 | 3.10 | 105.25M |
| Sep 21, 2026 | 2.78 | 2.79 | 2.18 | 2.56 | 94.20K |
About Decoy Therapeutics
Decoy Therapeutics (DCOY) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in HOUSTON, TX. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1615219.
DCOY board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Tess Burleson | Director | Sep 2, 2026 |
| Patricia G. Gauthier | Director | Sep 2, 2026 |
| Arnold C Hanish | Director | Sep 2, 2026 |
| Paul Lammers | Director | Sep 2, 2026 |
| Jonathan I Lieber | Director | Sep 2, 2026 |
| William K. Mcvicar | Director | Sep 2, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Barbara Louise Hibner | Chief Scientific Officer | Sep 2, 2026 |
| Peter Klaus Marschel | Chief Business Officer | Sep 2, 2026 |
| Frederick Ii Pierce | Chief Executive Officer | Sep 2, 2026 |
| Mark J Rosenblum | Chief Financial Officer | Sep 2, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Dec 30, 2025 | Arnold C Hanish | Sale | 15 | $0.64 |
| Dec 30, 2025 | Arnold C Hanish | Sale | 12 | $0.64 |
| Dec 30, 2025 | Arnold C Hanish | Sale | 15 | $0.64 |
| Dec 30, 2025 | Arnold C Hanish | Sale | 12 | $0.64 |
| Dec 30, 2025 | Arnold C Hanish | Sale | 15 | $0.64 |
| Dec 30, 2025 | Arnold C Hanish | Sale | 12 | $0.64 |
| Dec 30, 2025 | Arnold C Hanish | Sale | 15 | $0.64 |
| Dec 30, 2025 | Arnold C Hanish | Sale | 12 | $0.64 |
| Nov 20, 2025 | Arnold C Hanish | Buy | 5,000 | $0.75 |
| Nov 20, 2025 | Arnold C Hanish | Buy | 5,000 | $0.75 |
| Nov 20, 2025 | Arnold C Hanish | Buy | 5,000 | $0.75 |
| Nov 20, 2025 | Arnold C Hanish | Buy | 5,000 | $0.75 |
| Nov 20, 2025 | Mark J Rosenblum | Buy | 20,000 | $0.80 |
| Nov 20, 2025 | Mark J Rosenblum | Buy | 20,000 | $0.80 |
| Nov 20, 2025 | Mark J Rosenblum | Buy | 20,000 | $0.80 |
DCOY financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-12.52M | -129.10 | $-4.83M |
| Dec 31, 2024 | — | $-5.58M | -69.54 | $-4.53M |
| Dec 31, 2023 | — | $-12.54M | -30.74 | $-12.85M |
| Dec 31, 2022 | $0 | $-31.61M | -14.88 | $-17.60M |
| Dec 31, 2021 | $1.84M | $-12.77M | -7.72 | $-10.20M |
Latest balance sheet: total assets $9.00M, total liabilities $4.68M, cash $8.29M (as of Jun 30, 2026).
DCOY earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Jul 31, 2025 | 8-K Item 2.02 (results) | $107.82 |
| Jan 17, 2025 | 8-K Item 2.02 (results) | $484.20 |
| Aug 10, 2023 | 8-K Item 2.02 (results) | — |
| Nov 10, 2022 | 8-K Item 2.02 (results) | — |
| Aug 15, 2022 | 8-K Item 2.02 (results) | — |
| May 12, 2022 | 8-K Item 2.02 (results) | — |
| Mar 10, 2022 | 8-K Item 2.02 (results) | — |
| Aug 5, 2021 | 8-K Item 2.02 (results) | — |
| May 12, 2021 | 8-K Item 2.02 (results) | — |
| Nov 12, 2020 | 8-K Item 2.02 (results) | — |
| Aug 12, 2020 | 8-K Item 2.02 (results) | — |
| Jul 29, 2020 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on DCOY
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.